Literature DB >> 17570036

Expression of VEGF and its receptor genes in intracranial schwannomas.

Toshio Uesaka1, Tadahisa Shono, Satoshi O Suzuki, Akira Nakamizo, Hiroaki Niiro, Masahiro Mizoguchi, Toru Iwaki, Tomio Sasaki.   

Abstract

Vascular endothelial growth factor (VEGF) is considered to be a major regulator of angiogenesis in various brain tumors. In this study, we determined the expression levels of VEGF, and vascular endothelial growth factor receptor (VEGFR)-1 and -2 mRNA in 46 intracranial schwannomas by quantitative real-time PCR, and correlated these with various clinical factors or other molecular markers. We found that these tumors expressed significant amounts of VEGF mRNA in comparison with other brain tumors, including malignant gliomas and meningiomas. In addition, we performed immunohistochemical studies for VEGF and VEGFR-1, and confirmed that these tumors prominently express these proteins. The expression levels of VEGF and VEGFR-1 mRNA in recurrent tumors were higher than those in primary tumors. When we divided patients into two groups according to VEGF mRNA expression in the tumor, there was no significant difference in patient age, gender, or cranial nerves of origin between groups; however, the tumor volume tended to be larger in the high VEGF group than in the low VEGF group. The levels of VEGFR-1 mRNA and neurofibromatosis-2 mRNA in the high VEGF group were significantly greater than those in the low VEGF group. Levels of VEGFR-2 mRNA and DNA topoisomerase IIalpha mRNA, and the MIB-1 labeling index in the high VEGF group were slightly higher than those in the low VEGF group; however, the difference was not statistically significant. Based on these observations, the significance of VEGF and its receptor genes in intracranial schwannomas is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570036     DOI: 10.1007/s11060-007-9336-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  19 in total

1.  Acoustic neuroma with malignant transformation. Case report.

Authors:  K Hanabusa; A Morikawa; T Murata; W Taki
Journal:  J Neurosurg       Date:  2001-09       Impact factor: 5.115

2.  Expression of VEGF and its receptors in different brain tumors.

Authors:  Hongguang Huang; Janka Held-Feindt; Ralf Buhl; Hubertus M Mehdorn; Rolf Mentlein
Journal:  Neurol Res       Date:  2005-06       Impact factor: 2.448

3.  Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas.

Authors:  K Saito; M Kato; N Susaki; T Nagatani; T Nagasaka; J Yoshida
Journal:  Clin Neuropathol       Date:  2003 Jan-Feb       Impact factor: 1.368

4.  VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate.

Authors:  Per Cayé-Thomasen; Kim Werther; Amarnadh Nalla; Thorkild C Bøg-Hansen; Hans Jørgen Nielsen; Sven-Eric Stangerup; Jens Thomsen
Journal:  Otol Neurotol       Date:  2005-01       Impact factor: 2.311

5.  Size and growth rate of sporadic vestibular schwannoma: predictive value of information available at presentation.

Authors:  Amit Herwadker; Elizabeth A Vokurka; D Gareth R Evans; Richard T Ramsden; Alan Jackson
Journal:  Otol Neurotol       Date:  2005-01       Impact factor: 2.311

6.  Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery.

Authors:  Masahiro Shin; Keisuke Ueki; Hiroki Kurita; Takaaki Kirino
Journal:  Lancet       Date:  2002-07-27       Impact factor: 79.321

7.  Vestibular schwannoma management. Part II. Failed radiosurgery and the role of delayed microsurgery.

Authors:  B E Pollock; L D Lunsford; D Kondziolka; R Sekula; B R Subach; R L Foote; J C Flickinger
Journal:  J Neurosurg       Date:  1998-12       Impact factor: 5.115

8.  Expression of angiogenic growth factors in acoustic neurinoma.

Authors:  Jürgen Brieger; Anan Bedavanija; Hans-Anton Lehr; Jan Maurer; Wolf J Mann
Journal:  Acta Otolaryngol       Date:  2003-12       Impact factor: 1.494

9.  cDNA microarray analysis of vestibular schwannomas.

Authors:  D Bradley Welling; John M Lasak; Elena Akhmametyeva; Bobak Ghaheri; Long-Sheng Chang
Journal:  Otol Neurotol       Date:  2002-09       Impact factor: 2.311

10.  Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours.

Authors:  M B Parliament; M J Allalunis-Turner; A J Franko; P L Olive; R Mandyam; C Santos; B Wolokoff
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  18 in total

1.  Histopathological vascular investigation of the peritumoral brain zone of glioblastomas.

Authors:  Ryota Tamura; Kentaro Ohara; Hikaru Sasaki; Yukina Morimoto; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2017-11-29       Impact factor: 4.130

2.  Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.

Authors:  Hon-Kit Wong; Akio Shimizu; Nathaniel D Kirkpatrick; Igor Garkavtsev; Annie W Chan; Emmanuelle di Tomaso; Michael Klagsbrun; Rakesh K Jain
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

Review 3.  Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.

Authors:  Sylwia Ammoun; C Oliver Hanemann
Journal:  Nat Rev Neurol       Date:  2011-06-07       Impact factor: 42.937

Review 4.  Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis related to or comparable with mechanisms seen in inflammatory pathways? Part II: angiogenesis- and inflammation-related molecular pathways, tumor-associated macrophages, and possible therapeutic implications: a comprehensive review.

Authors:  Yosef Laviv; Burkhard Kasper; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2017-03-11       Impact factor: 3.042

5.  Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2.

Authors:  H A Riina; J-K Burkhardt; A Santillan; L Bassani; A Patsalides; J A Boockvar
Journal:  Interv Neuroradiol       Date:  2012-06-04       Impact factor: 1.610

6.  Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.

Authors:  Audrey Hochart; Vianney Gaillard; Marc Baroncini; Nicolas André; Jean-Pierre Vannier; Matthieu Vinchon; Frederique Dubrulle; Jean-Paul Lejeune; Christophe Vincent; Véronique Nève; Héléne Sudour Bonnange; Nicolas Xavier Bonne; Pierre Leblond
Journal:  J Neurooncol       Date:  2015-05-29       Impact factor: 4.130

7.  Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.

Authors:  John A Boockvar; Apostolos J Tsiouris; Christoph P Hofstetter; Ilhami Kovanlikaya; Sherese Fralin; Kartik Kesavabhotla; Stephen M Seedial; Susan C Pannullo; Theodore H Schwartz; Philip Stieg; Robert D Zimmerman; Jared Knopman; Ronald J Scheff; Paul Christos; Shankar Vallabhajosula; Howard A Riina
Journal:  J Neurosurg       Date:  2010-10-22       Impact factor: 5.115

8.  Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.

Authors:  Victor-Felix Mautner; Rosa Nguyen; Hannes Kutta; Carsten Fuensterer; Carsten Bokemeyer; Christian Hagel; Reinhard E Friedrich; Jens Panse
Journal:  Neuro Oncol       Date:  2009-10-20       Impact factor: 12.300

Review 9.  Histologic Evidence for Arteriovenous Malformation-Like Vasculature Occurring within an Intracerebral Schwannoma: A Case Report and Review of the Literature.

Authors:  Bayard R Wilson; Jeffrey A Steinberg; Vivian Snyder; Michael N Jiang; Bob S Carter
Journal:  World Neurosurg       Date:  2016-06-03       Impact factor: 2.104

10.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.